ABX-1431
Phase 2- Indications
- Tourette syndrome, Neuropathic pain
Company intelligence / Profile preview
Abide Therapeutics
San Diego, California, United Statesorpha.net ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Phase 2
01
Overview
Abide’s lead program, ABX‑1431—a potent and selective MGLL inhibitor—was in Phase 2 trials for Tourette syndrome and entering Phase 2 for other neurological diseases at the time of its acquisition by Lundbeck. The company’s platform enabled rapid identification and development of small-molecule inhibitors targeting the under-explored serine hydrolase enzyme family. No commercial products were reported prior to acquisition.
- Therapeutic areas
- ImmunologyPsychiatryNeurologyMetabolic Disorders
- Modalities
- Small molecules (notably serine hydrolase inhibitors)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Celgene – strategic collaboration on inflammation/immunology drug discovery/developmentMerck & Co. – partnership to develop small-molecule therapies for metabolic disease/type II diabetes
Beyond the preview
Go deeper on Abide Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abide Therapeutics.